CRISPR Therapeutics AG (NASDAQ:CRSP) saw a large decrease in short interest in December. As of December 31st, there was short interest totalling 3,610,000 shares, a decrease of 16.2% from the December 15th total of 4,310,000 shares. Based on an average daily trading volume, of 1,320,000 shares, the days-to-cover ratio is presently 2.7 days.
Shares of CRISPR Therapeutics stock traded down $10.16 during trading on Monday, hitting $199.88. 4,004,905 shares of the stock traded hands, compared to its average volume of 2,847,970. The stock has a market cap of $14.23 billion, a price-to-earnings ratio of -61.31 and a beta of 2.37. CRISPR Therapeutics has a 52 week low of $32.30 and a 52 week high of $220.20. The firm's fifty day moving average is $158.70 and its 200-day moving average is $108.57.
CRISPR Therapeutics (NASDAQ:CRSP) last issued its earnings results on Monday, November 2nd. The company reported ($1.32) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($1.18) by ($0.14). The firm had revenue of $0.15 million during the quarter, compared to analysts' expectations of $2.22 million. CRISPR Therapeutics had a negative return on equity of 20.72% and a negative net margin of 273.10%. The firm's quarterly revenue was down 99.9% compared to the same quarter last year. During the same period in the prior year, the company earned $2.40 EPS. As a group, sell-side analysts expect that CRISPR Therapeutics will post -4.97 earnings per share for the current year.
A number of research firms have recently commented on CRSP. Truist raised their price objective on shares of CRISPR Therapeutics from $170.00 to $210.00 in a research report on Tuesday, January 12th. Bank of America assumed coverage on shares of CRISPR Therapeutics in a report on Monday, October 5th. They issued a "buy" rating and a $110.00 price target for the company. Oppenheimer upped their price target on shares of CRISPR Therapeutics from $105.00 to $155.00 and gave the stock an "outperform" rating in a report on Monday, December 7th. Royal Bank of Canada began coverage on CRISPR Therapeutics in a research note on Thursday, October 22nd. They set a "sector perform" rating and a $110.00 price objective for the company. Finally, Roth Capital upped their target price on CRISPR Therapeutics from $115.00 to $170.00 and gave the stock a "buy" rating in a research note on Monday, December 7th. Two investment analysts have rated the stock with a sell rating, four have issued a hold rating and eleven have assigned a buy rating to the stock. CRISPR Therapeutics currently has a consensus rating of "Buy" and a consensus target price of $136.07.
In other news, Director Bradley J. Phd Bolzon sold 171,004 shares of CRISPR Therapeutics stock in a transaction on Monday, December 7th. The stock was sold at an average price of $154.53, for a total value of $26,425,248.12. Following the completion of the transaction, the director now directly owns 40,648 shares in the company, valued at $6,281,335.44. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, VP Tony W. Ho sold 23,551 shares of the business's stock in a transaction on Monday, December 21st. The shares were sold at an average price of $149.23, for a total value of $3,514,515.73. The disclosure for this sale can be found here. Insiders have sold a total of 355,203 shares of company stock worth $51,155,283 over the last 90 days. 21.40% of the stock is currently owned by corporate insiders.
Several hedge funds have recently added to or reduced their stakes in CRSP. Vigilant Capital Management LLC bought a new stake in CRISPR Therapeutics in the third quarter worth $25,000. Webster Bank N. A. bought a new stake in shares of CRISPR Therapeutics in the 3rd quarter valued at about $27,000. Summit X LLC purchased a new stake in CRISPR Therapeutics during the 3rd quarter valued at about $34,000. Nachman Norwood & Parrott Inc purchased a new stake in CRISPR Therapeutics during the 3rd quarter valued at about $42,000. Finally, Huntington National Bank grew its position in CRISPR Therapeutics by 45.0% during the 4th quarter. Huntington National Bank now owns 290 shares of the company's stock worth $44,000 after acquiring an additional 90 shares during the last quarter. 66.43% of the stock is currently owned by institutional investors.
CRISPR Therapeutics Company Profile
CRISPR Therapeutics AG, a gene editing company, focuses on developing transformative gene-based medicines for serious human diseases. It develops its products using Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), a gene editing technology that allows for precise directed changes to genomic DNA.
Recommended Story: Real Estate Investment Trust (REIT) ETF
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected]
8 Retail Stocks to Own For the Long Haul
There are more than 500 national retailers traded on the NYSE and the NASDAQ. Given the sheer number of big box stores, warehouse clubs, restaurant chains, and other retail stores listed on public markets, it can be hard to identify which retailers will outperform the market.
Fortunately, some of Wall Street's top analysts have already done most of the work for us.
Every year, analysts issue approximately 4,200 distinct recommendations for retail companies. Analysts may not always get their "buy" ratings right, but it's worth taking a hard look when several analysts from different brokerages and research firms are giving "strong-buy" and "buy" ratings to the same retailer.
This slide show lists the 8 retail companies with the highest average analyst recommendations from Wall Street's equities research analysts over the last 12 months.
View the "8 Retail Stocks to Own For the Long Haul".